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Background: Large cohort studies of patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) have linked 
the CYP2C19*2 allele (c.681G>A) to reduced clopidogrel metabolism, increased platelet reactivity and major cardiovascular events. However, the 
feasibility of performing routine genotyping and platelet function testing in patients undergoing elective PCI in a high-volume cardiac catheterization 
lab is unknown.
Methods: Consecutive patients undergoing an elective cardiac catheterization and possible PCI with a drug eluting stent (DES) were genotyped 
for CYP2C19 loss-of-function alleles (*2 - *8) in a clinical laboratory. Blood was sent for genotyping prior to the cardiac catheterization procedure 
during the consent process. Based on CYP2C19 genotype, subjects were categorized as wild-type (*1/*1), heterozygous (e.g., *1/*2, *1/*3, 
*1/*8) or homozygous (e.g., *2/*2) and further risk stratified after PCI based on high risk clinical features. Subjects with ≥1 high risk features 
underwent platelet function testing with the VerifyNow® assay. Results were expressed as percent platelet inhibition (PI) and platelet reactivity units 
(PRU).
Results: Among the entire tested population (n=113), eighty-two (72%) patients underwent a PCI with a DES. No CYP2C19*4, *5, *6, or *7 carriers 
were detected. Results of genotyping were received on average 8 hours and platelet reactivity within 15 minutes from sampling. Sixty-seven (58%), 
41 (36%), and 5 (4.3%) subjects had wild-type, heterozygous, and homozygous CYP2C19 genotypes, respectively. Measured PI was 42.1%±25.4 vs 
26.3%±25.7 (p<0.05), and PRU was 208.3±94.6 vs 255.3±107.6 (p=0.13) in wild-type and heterozygous subjects, respectively.
Conclusion: Routine CYP2C19 genotyping and platelet function testing is feasible in a high-volume cardiac catheterization lab and in the 
population studied more than one-third of subjects carried a CYP2C19 loss-of-function *2 allele with a statistically significant reduction in percent 
platelet inhibition. The clinical value in performing these tests and individualizing antiplatelet therapies in this setting remain unclear.
